CESTAT allows CENVAT credit appeal for duty-free vaccine manufacture, Department fails to prove manufacturing

CESTAT Chandigarh allowed the appeal regarding reversal of CENVAT credit for duty-free Hemophilus Vaccine manufacture. The Department failed to establish that the appellant manufactured the exempted product, as evidence showed a separate entity held the manufacturing license and operated under lease agreements. Drug Controller confirmed different licenses were issued to separate entities. The tribunal found no grounds to invoke Rule 6(3) of CCR, 2004, noting drug manufacturing requires regulatory oversight and cannot occur secretly. Additionally, Telangana HC precedent supported that Rule 6 lacks recovery mechanisms for the 10% amount, with Department having recourse under Rule 14 if needed.

---

---

ISSUES PRESENTED AND CONSIDERED

1. Whether Rule 6(3) of the Cenvat Credit Rules, 2004 can be invoked to demand reversal (10% of value) where final products cleared duty-free are alleged to have been manufactured by the assessee, or whether such demand can be made only where the assessee itself manufactured the exempted goods.

2. Whether Rule 6(3) of CCR, 2004 confers on revenue the power to select and impose one of the alternative compliance options provided therein on a taxpayer who failed to exercise any option.

3. Whether the extended period of limitation for demand is invocable where the Department relied on statutory records (RG-1/RG-23A) and where the question of actual manufacturer (third party operating in same premises) was not adequately verified by the Department.

4. Whether, as an alternative to invoking Rule 6(3), the Department's remedy for alleged wrongful availment of CENVAT credit is to proceed under Rule 14 of CCR, 2004 to recover wrongly taken or utilised credit.

ISSUE-WISE DETAILED ANALYSIS

Issue 1 - Applicability of Rule 6(3) where manufacture of exempted goods is disputed

Legal framework: Rule 6(3) CCR, 2004 prescribes options to be exercised by a manufacturer/service provider who uses inputs/input services for both dutiable and exempted goods/services, including a prescribed percentage reversal (10% for exempted goods in relevant period).

Precedent Treatment: Tribunal and High Court decisions (cited: Tiara Advertising; Tribunal followings in SPAC Taopica and Nava Bharat) have interpreted the rule and related remedies.

Interpretation and reasoning: The Court examined evidence produced by the appellant indicating that production of the Hemophilus vaccine was undertaken by a separate legal entity operating in the same compound (agreement for manufacturing facility and services, lease entries in associate's accounts, separate drug manufacturing licence for the third party, reports indicating existence of separate excise records, RG-1/RG-23A entries reflecting receipts rather than manufacture, affidavit). The Tribunal found the Commissioner did not effectively controvert or verify this evidence (no independent verification with Drug Authorities; simplistic reliance on assessee's RG-1 entries). Given that the remand point was whether the vaccine was manufactured by the separate entity, and the Department failed to negate the claim on sound legal reasoning, invoking Rule 6(3) against the appellant was legally unsustainable.

Ratio vs. Obiter: Ratio - Where the Department fails to establish that the assessee itself manufactured exempted goods, Rule 6(3) cannot be invoked against that assessee to demand the prescribed reversal. Obiter - Observations regarding the imprudence of merely alleging contravention of Drug Laws without verification.

Conclusions: Demand under Rule 6(3) cannot be sustained against the assessee on the facts because the Department did not negate the evidence that a distinct entity manufactured the exempted vaccine; therefore Rule 6(3) was inapplicable as enforced by the adjudicating authority.

Issue 2 - Whether revenue may choose an option under Rule 6(3) on behalf of a defaulting assessee

Legal framework: Rule 6(3) provides alternate options for taxpayers who do not maintain separate accounts for inputs/input services consumed in dutiable and exempted outputs.

Precedent Treatment: High Court judgment in Tiara Advertising (Telangana) held that Rule 6(3) merely offers options to the taxpayer and does not empower authorities to choose an option for the taxpayer; authorities may instead reject claims or proceed under Rule 14 for wrongly availed credit. Tribunal decisions have followed this approach.

Interpretation and reasoning: The Tribunal accepted the High Court's interpretation that the statutory scheme does not vest the revenue with power to make the taxpayer's choice under Rule 6(3). If the assessee fails to exercise the option, authorities may either reject the credit claim or invoke recovery provisions (Rule 14) but cannot unilaterally impose the 5%/6%/10% selection under Rule 6(3).

Ratio vs. Obiter: Ratio - Revenue cannot unilaterally select and impose an option under Rule 6(3) for an assessee who failed to exercise the statutory options; recovery of wrongly availed credit must follow Rule 14. Obiter - The applicability of Rule 6(3) as a compliance mechanism where the assessee validly exercised an option.

Conclusions: The Tribunal adopts the view that Rule 6(3) does not empower authorities to make the choice on behalf of the assessee; instead, where credit is wrongly availed the appropriate remedy is recourse to Rule 14.

Issue 3 - Invocation of extended limitation where statutory records were available and manufacturer was disputed

Legal framework: Extended period of limitation is available where facts leading to evasion were not available to revenue; ordinary period applies where primary records would disclose the relevant facts.

Precedent Treatment: Cases cited by parties (CCE v. ITC Ltd., Praj Industries, Cellular Ltd.) address the circumstances in which extended period can be invoked; Tribunal noted these precedents but found them unnecessary to decide once merits were resolved in favour of assessee.

Interpretation and reasoning: The Tribunal held that because the appellant's case was decided on merits (i.e., the Department failed to displace evidence that manufacture was by a third party), the question of limitation becomes redundant. The Tribunal also noted that the Department relied upon RG-1/RG-23A entries but failed to verify or negate the documentary evidence showing third-party manufacture; thus reliance on primary records alone without verification could not justify extended period invocation on these facts.

Ratio vs. Obiter: Obiter - Determination on limitation is unnecessary given decision on merits; however, the Tribunal's reasoning suggests that mere presence of RG-1 entries does not automatically sustain extended period if the Department fails further verification.

Conclusions: Issue of extended limitation was rendered redundant by the Tribunal's merits finding; revenue's invocation of extended period not decisive after departmental failure to verify manufacturing claims.

Issue 4 - Proper remedy for alleged wrongful availment of CENVAT credit (Rule 14) as alternative to Rule 6(3)

Legal framework: Rule 14 CCR, 2004 empowers recovery of CENVAT credit which has been taken or utilised wrongly along with interest.

Precedent Treatment: Tiara Advertising and subsequent Tribunal decisions endorse using Rule 14 to recover wrongly availed credit rather than compulsion under Rule 6(3).

Interpretation and reasoning: The Tribunal found that although Rule 14 was invoked by the Department in the present proceedings, the Commissioner sought recovery by applying the 10% mechanism of Rule 6(3) rather than quantifying and recovering wrongly availed credit under Rule 14. The Tribunal agreed with precedent that Rule 6(3) does not provide a recovery mechanism that the revenue may unilaterally impose; Rule 14 is the statutory route for recovery of wrongly availed credit.

Ratio vs. Obiter: Ratio - Recovery of wrongly availed CENVAT credit must be effected under Rule 14; Rule 6(3) does not supply an alternate enforcement power for revenue to impose a percentage where the taxpayer did not elect an option. Obiter - Practical observations on the Department's failure to pursue verification under Rule 14 in a focussed manner.

Conclusions: On the alternate submission the Tribunal held in favour of the assessee - the Department should have proceeded under Rule 14 to recover any wrongly availed credit rather than impose the 10% reversal under Rule 6(3).

Overall Conclusion

The appeal is allowed: on the factual and legal analysis the Department failed to establish that the appellant manufactured the exempted Hemophilus vaccine; Rule 6(3) was improperly invoked and, in any event, the statutory scheme requires recovery of wrongly availed credit under Rule 14 rather than unilateral selection of options by revenue. Consequential relief to follow as per law.

---